Moreover, loss of KMT5A catalytic activity by KMT5A depletion or KMT5A-selective inhibitor, and combined with YAP signaling inhibition significantly impairs breast cancer progression and metastasis. The gene discussed is KMT5A; the disease is breast carcinoma.